Suppression of tumorigenicity 2 (ST2)


Meijers WC, Van del Velde AR, Kobold ACM, et al, 2017, Eur J Hearth Failure , 19, 357-65 , Variability of biomarkers in patients with chronic heart failure and healthy controls


Total Score


Parameter Score
1. Scale A
2. Study Population A
3. Samples C
4. Measurand C
5. Pre-Analytical B
6. Replicate Analysis A
7. Steady State A
8. Outlier Analysis C
9. Normality A
10. Variance Homogeneity C
12. CI A
13. No of Results A
14. Concentrations A
15. Total Score C3,4,8,10

Item Details

Parameter Score
Matrix Plasma
Measurand Suppression of tumorigenicity 2 (ST2)
Unit ng / mL
Overall Analytical Principle Method Unknown
Number of Subjects 83
Number of Subjects included in BV estimation 83
Ethinicity Unknown
Age Mean / Median 64.0
Age Min
Age Max
Age SD 10.0
Number of Males 79
Number of Females 4
State of Well Being
Non-healthy (excl pregnant)
Study Duration Length 3
Study Duration Units Week
Sampling Intervals, e.g. X sample(s) per Interval Unit 1
Interval Units Week
Sampling Times Start Time:
End Time:
Number of Samples 3
Average Number of Samples Used for BV Estimation 3.0
Average Number of Replicates
Estimates of CVi 15.0
Calculated Confidence Intervals of CVi Lower: 13.48, Upper: 16.87
Estimates of CVg 36.9
Calculated Confidence Intervals of CVg Lower: 31.73, Upper: 43.86
Analytical CV 2.9
Calculated Confidence Intervals of Analytical CV Lower: 2.26, Upper: 4.03
Measurand Mean 27.5
Measurand Min 27.9
Measurand Max 33.6
Measurand SD